Nelson Roberts Investment Advisors Lowers stake in Illumina (ILMN)

Illumina (ILMN) : Nelson Roberts Investment Advisors reduced its stake in Illumina by 2.6% during the most recent quarter end. The investment management company now holds a total of 33,675 shares of Illumina which is valued at $5,623,388 after selling 900 shares in Illumina , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Illumina makes up approximately 2.02% of Nelson Roberts Investment Advisors’s portfolio.

Other Hedge Funds, Including , Blair William Coil boosted its stake in ILMN in the latest quarter, The investment management firm added 37,932 additional shares and now holds a total of 118,730 shares of Illumina which is valued at $19,949,015. Illumina makes up approx 0.18% of Blair William Coil’s portfolio.Ashfield Capital Partners reduced its stake in ILMN by selling 29,031 shares or 34.42% in the most recent quarter. The Hedge Fund company now holds 55,306 shares of ILMN which is valued at $9,292,514. Illumina makes up approx 0.71% of Ashfield Capital Partners’s portfolio. Gerstein Fisher sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 1,526 shares of ILMN which is valued $256,399.Sg Americas Securities reduced its stake in ILMN by selling 3,667 shares or 27.33% in the most recent quarter. The Hedge Fund company now holds 9,749 shares of ILMN which is valued at $1,609,072. Illumina makes up approx 0.01% of Sg Americas Securities’s portfolio.

Illumina closed down -0.7 points or -0.41% at $171.67 with 10,15,440 shares getting traded on Friday. Post opening the session at $171.83, the shares hit an intraday low of $169.81 and an intraday high of $174.07 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.

Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by CL King to ” Neutral” on Aug 22, 2016. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.